Progesterone signalling in breast cancer: a neglected hormone coming into the limelight

Understanding the biology of the breast and how ovarian hormones impinge on it is key to rational new approaches in breast cancer prevention and therapy. Because of the success of selective oestrogen receptor modulators (SERMs), such as tamoxifen, and aromatase inhibitors in breast cancer treatment, oestrogens have long received the most attention. Early progesterone receptor (PR) antagonists, however, were dismissed because of severe side effects, but awareness is now increasing that progesterone is an important hormone in breast cancer. Oestrogen receptor-α (ERα) signalling and PR signalling have distinct roles in normal mammary gland biology in mice; both ERα and PR delegate many of their biological functions to distinct paracrine mediators. If the findings in the mouse model translate to humans, new preventive and therapeutic perspectives might open up.

[1]  L. Rydén,et al.  Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.

[2]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[3]  J. Li,et al.  Targeting RANKL to a specific subset of murine mammary epithelial cells induces ordered branching morphogenesis and alveologenesis in the absence of progesterone receptor expression , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[5]  Celine M Vachon,et al.  Case-control study of increased mammographic breast density response to hormone replacement therapy. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[6]  H. Dinh,et al.  RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini , 2006, Molecular and Cellular Biology.

[7]  K. Byth,et al.  Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. , 2005, Molecular endocrinology.

[8]  B. O’Malley,et al.  Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. , 1995, Genes & development.

[9]  Mark D. Aupperlee,et al.  Progesterone receptor isoforms A and B: temporal and spatial differences in expression during murine mammary gland development. , 2005, Endocrinology.

[10]  Kornelia Polyak,et al.  Cellular heterogeneity and molecular evolution in cancer. , 2013, Annual review of pathology.

[11]  S. Haslam,et al.  Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers , 2010, Hormones & cancer.

[12]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[13]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[14]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[15]  D. Lacey,et al.  The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.

[16]  K. Nelson,et al.  Lactoferrin expression in the mouse reproductive tract during the natural estrous cycle: correlation with circulating estradiol and progesterone. , 1992, Endocrinology.

[17]  W. Boon,et al.  Alternative 5′-untranslated first exons of the mouse Cyp19A1 (aromatase) gene , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  Wassim Raffoul,et al.  Progesterone/RANKL Is a Major Regulatory Axis in the Human Breast , 2013, Science Translational Medicine.

[19]  K. Kerlikowske,et al.  Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Zvelebil,et al.  Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate , 2008, BMC Genomics.

[21]  A. Ashworth,et al.  Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland , 2007, The Journal of cell biology.

[22]  M. Barcellos-Hoff,et al.  Growth Factors, Cytokines, Cell Cycle Molecules Proliferation of Estrogen Receptor- -Positive Mammary Epithelial Cells Is Restrained by Transforming Growth Factor- 1 in Adult Mice , 2005 .

[23]  S. Haslam,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Hormone Replacement Therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation , 2022 .

[24]  R. Collins,et al.  EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALS , 1988, The Lancet.

[25]  M. Widschwendter,et al.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer , 2010, Nature.

[26]  V. McCormack,et al.  Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[27]  H M Jensen,et al.  On the origin and progression of ductal carcinoma in the human breast. , 1973, Journal of the National Cancer Institute.

[28]  R. Greil,et al.  Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy , 2008, Clinical Cancer Research.

[29]  J. Bergh,et al.  Identification of molecular apocrine breast tumours by microarray analysis , 2005, Breast Cancer Research.

[30]  J. Manson,et al.  Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. , 2012, The Lancet. Oncology.

[31]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2008 .

[32]  R. Moon,et al.  WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.

[33]  F. DeMayo,et al.  Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. , 2000, Science.

[34]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[35]  J. A. Andersen,et al.  Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. , 1987, British Journal of Cancer.

[36]  R. Nusse,et al.  Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland. , 2012, Cell stem cell.

[37]  F. DeMayo,et al.  Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[39]  D. Edwards,et al.  Transcriptional response of the murine mammary gland to acute progesterone exposure. , 2008, Endocrinology.

[40]  S. Haslam,et al.  Effect of oestradiol on progesterone receptors in normal mammary glands and its relationship with lactation. , 1979, The Biochemical journal.

[41]  Marie-Liesse Asselin-Labat,et al.  The Ets transcription factor Elf5 specifies mammary alveolar cell fate. , 2008, Genes & development.

[42]  C. Lawton.  Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women , 2010 .

[43]  R. Weinberg,et al.  A paracrine role for the epithelial progesterone receptor in mammary gland development. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Chambon,et al.  Paracrine signaling through the epithelial estrogen receptor α is required for proliferation and morphogenesis in the mammary gland , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Lowe,et al.  Age at first birth and breast cancer risk. , 1970, Bulletin of the World Health Organization.

[46]  F. Schmidt.  Meta-Analysis , 2008 .

[47]  A. Ashworth,et al.  CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells , 2005, Breast Cancer Research.

[48]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[49]  T. Longacre,et al.  A Correlative Morphologic Study of Human Breast and Endometrium in the Menstrual Cycle , 1986, The American journal of surgical pathology.

[50]  C. Caligioni.  Assessing Reproductive Status/Stages in Mice , 2009, Current protocols in neuroscience.

[51]  J. Ellenberg,et al.  Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. , 2003, Molecular cell.

[52]  D. Johnston,et al.  Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. , 1996, Carcinogenesis.

[53]  Chenguang Wang,et al.  Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.

[54]  Cathrin Brisken,et al.  Hormone action in the mammary gland. , 2010, Cold Spring Harbor perspectives in biology.

[55]  D. Branstetter,et al.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.

[56]  C. Daniel,et al.  Direct action of 17 beta-estradiol on mouse mammary ducts analyzed by sustained release implants and steroid autoradiography. , 1987, Cancer research.

[57]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[58]  A. Rocha,et al.  Distinct stem cells contribute to mammary gland development and maintenance , 2011, Nature.

[59]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[60]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[61]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer , 1996 .

[62]  A. Howell,et al.  Dissociation between steroid receptor expression and cell proliferation in the human breast. , 1997, Cancer research.

[63]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.

[64]  D. G. Hoel,et al.  ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer , 1983, Nature.

[65]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[66]  C. Clarke,et al.  Progesterone induces adult mammary stem cell expansion , 2010, Nature.

[67]  B. V. VON Schoultz,et al.  Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. , 2002, American journal of obstetrics and gynecology.

[68]  Jinfeng Li,et al.  [WHO classification of tumors of the breast]. , 2014, Zhonghua wai ke za zhi [Chinese journal of surgery].

[69]  F. Sablitzky,et al.  ID4 regulates mammary gland development by suppressing p38MAPK activity , 2011, Development.

[70]  H. Sutton,et al.  RAPID INDUCTION OF MAMMARY CARCINOMA IN THE RAT AND THE INFLUENCE OF HORMONES ON THE TUMORS , 1959, Journal of Experimental Medicine.

[71]  P. Chambon,et al.  Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. , 2000, Development.

[72]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[73]  S. Haslam,et al.  Progesterone action in normal mouse mammary gland. , 1990, Endocrinology.

[74]  R. Blamey,et al.  Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  Yun Wu,et al.  Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. , 2007, The American journal of pathology.

[76]  J. Pollard,et al.  Macrophages promote collagen fibrillogenesis around terminal end buds of the developing mammary gland , 2006, Developmental dynamics : an official publication of the American Association of Anatomists.

[77]  L. Norton,et al.  Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation , 2012, Breast Cancer Research and Treatment.

[78]  Adrian V. Lee,et al.  Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. , 2002, Molecular endocrinology.

[79]  S. Nandi,et al.  Endocrine control of mammarygland development and function in the C3H/ He Crgl mouse. , 1958, Journal of the National Cancer Institute.

[80]  J. Masters,et al.  Cyclic Variation of DNA synthesis in human breast epithelium. , 1977, Journal of the National Cancer Institute.

[81]  J. Visvader,et al.  Control of mammary stem cell function by steroid hormone signalling , 2010, Nature.

[82]  Mark D. Aupperlee,et al.  Differential hormonal regulation and function of progesterone receptor isoforms in normal adult mouse mammary gland. , 2007, Endocrinology.

[83]  Beth A Reboussin,et al.  Postmenopausal hormone therapy and change in mammographic density. , 2003, Journal of the National Cancer Institute.

[84]  R. Weinberg,et al.  IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. , 2002, Developmental cell.

[85]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[86]  P. Chambon,et al.  Effect of single and compound knockouts of estrogen receptors α (ERα) and β (ERβ) on mouse reproductive phenotypes , 2000 .

[87]  J. Cheng,et al.  Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.

[88]  C. Brisken,et al.  Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland , 2010, Proceedings of the National Academy of Sciences.

[89]  J. Russo,et al.  Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland , 1999, Breast Cancer Research and Treatment.

[90]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[91]  Shiuan Chen,et al.  An expression study of hormone receptors in spontaneously developed, carcinogen-induced and hormone-induced mammary tumors in female Noble rats. , 2003, International journal of oncology.

[92]  W. R. Lyons.  Hormonal synergism in mammary growth , 1958, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[93]  Cathrin Brisken,et al.  Amphiregulin is an essential mediator of estrogen receptor α function in mammary gland development , 2007, Proceedings of the National Academy of Sciences.

[94]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[95]  Z. Werb,et al.  Extracellular matrix degradation and remodeling in development and disease. , 2011, Cold Spring Harbor perspectives in biology.

[96]  K. Horwitz,et al.  Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[97]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.

[98]  R. Weinberg,et al.  Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. , 2000, Genes & development.

[99]  N. Boyd,et al.  Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.

[100]  E. Schmidt,et al.  IKKα Provides an Essential Link between RANK Signaling and Cyclin D1 Expression during Mammary Gland Development , 2001, Cell.

[101]  F. Climent,et al.  RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. , 2012, Cancer research.

[102]  R. Sitruk-Ware.  Pharmacological profile of progestins. , 2008, Maturitas.

[103]  F. Clavel-Chapelon,et al.  Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort , 2005, International journal of cancer.

[104]  J. Rosen,et al.  C/EBPβ (CCAAT/Enhancer Binding Protein) Controls Cell Fate Determination during Mammary Gland Development , 2000 .

[105]  C. Purdie,et al.  High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer , 2010, International journal of cancer.

[106]  A. Sivachenko,et al.  Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.

[107]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.